The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article ...
SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today the U.S. Centers for Medicare & Medicaid Services (CMS) is ...
Dexcom is also consistently rated the #1 CGM brand in independent patient surveys 5. In addition to integration with the t:slim X2 Pump, dynamic glucose data from the Dexcom G5 Mobile CGM can be ...
The Food and Drug Administration (FDA) has approved the Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System, the first fully mobile real-time diabetes management device for adults and children ...
Share price of DexCom, Inc.DXCM jumped 4.8% on Aug 25, following the FDA approval of the DexCom G5 Mobile Continuous Glucose Monitoring (CGM) System. The fully portable product is the first and ...
It’s a pretty good day for San Diego-based Dexcom. The company announced that it won CE Mark approval for its G5 continuous glucose monitor in the European Union. This means the device will be ...
As expected, an FDA panel voted in favor of giving Dexcom’s ($DXCM) G5 continuous glucose monitor a nonadjunctive indication that would allow it to be used in place ...
The agreement paves the way for those over age 65 to gain access to continuous glucose monitoring, following a historic policy change. Ascensia Diabetes Care and Dexcom have reached an agreement that ...
Dexcom Executive Vice President and Chief Commercial Officer RIck Doubleday visited The American Journal of Managed Care® to discuss Medicare reimbursement for the Dexcom G5 and a new partnership with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback